$34.20
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Composition active ingredients: ethinylestradiol, drospirenone; calcium levomefolate 1 package contains 28 film-coated tablets (21 orange tablets and 7 light orange tablets) 1 orange tablet contains 0.03 mg ethinyl estradiol, 3 mg drospirenone and 0.451 mg calcium levomefolate excipients: lactose, microcrystalline cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, magnesium stearate, polyethylene glycol 6000, talc, titanium dioxide (E 171), iron oxide yellow (E172), iron oxide red (E 172). 1 light orange tablet contains 0.451 mg calcium levomefolate excipients: lactose, microcrystalline cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, magnesium stearate, polyethylene glycol 6000, talc, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172) ).

Dosage form Film-coated tablets. Pharmacological group Hormones of the gonads and drugs used in the pathology of the genital area. Hormonal contraceptives for systemic use. ATC code G0ZA A12. Indications Oral contraception with additional anti-mineralocorticoid and antiandrogenic effects, especially in the presence of hormone-dependent fluid retention, manifests itself in swelling and weight gain, as well as in acne (acne) and excessive oily skin and hair (seborrhea). Ensuring folate status in women who have opted for oral contraception. Contraindications The drug Yarina Plus should not be used in the presence of at least one of the following conditions or diseases. If any of these conditions or diseases occurs for the first time during the use of the drug, it should be stopped immediately. Venous or arterial thrombotic / thromboembolic events (eg deep vein thrombosis, pulmonary embolism, myocardial infarction) or a history of cerebrovascular disorders. A history of prodromal symptoms of thrombosis (eg, transient cerebrovascular accident, angina pectoris). The presence of severe or multiple risk factors for the development of venous or arterial thrombosis may also be a contraindication for use. Migraine with a history of focal neurological symptoms. Diabetes mellitus with vascular lesions. Severe liver disease until liver function tests return to normal. Severe renal failure or acute renal failure. A history of liver tumors (benign or malignant).

Or suspected hormone-dependent tumors (for example, of the genitals or mammary glands). Vaginal bleeding of unknown etiology. Or a presumed pregnancy. Hypersensitivity to active substances or to any of the components of the drug. Dosage and administration With the correct use of combined oral contraceptives (COCs), the degree of ineffectiveness is approximately 1% per year. If you skip taking pills or use them incorrectly, the degree of ineffectiveness may increase. The tablets should be taken daily according to the order indicated on the package, at about the same time with a small amount of liquid. The drug is taken 1 tablet per day for 28 consecutive days. Taking pills from each next pack should be started the next day after taking the last pill from the pack, has ended. Withdrawal bleeding usually begins 2-3 days after you start taking the light orange hormone-free pills (last row in the package), and it may not end until you start taking the pills from the next package. The beginning of the use of the drug Yarina Plus Hormonal contraceptives in the previous period (last month) were not used. Taking pills should be started on the first day of the natural cycle (ie, on the first day of menstrual bleeding). You can also start taking it from day 2-5, but in this case it is necessary to use an additional method of contraception (for example, a barrier method) during the first 7 days of taking the drug. Switching from another oral contraceptive (COC), vaginal ring or transdermal patch It is advisable to start taking Yarina Plus tablets the next day after taking the last hormone pills of the previous COC, but no later than the next day after a break in taking the pills or after taking placebo tablets of the previous COC. In the case of using a contraceptive vaginal ring or transdermal patch, you should start taking the drug Yarina Plus on the day the drug is removed, but no later than the day when the next use of these drugs is necessary. Switching from a method based on the use of only progestogen ("mini-pills", injections, implants) or an intrauterine system with a progestogen You can start taking Yarina Plus any day after you stop taking "mini-pills" (in the case of an implant or intrauterine system - on the day of their removal, in case of injection.